Trifluoromethyldeschloroketamine
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
Chemical and physical data | |
Formula | C14H16F3NO |
Molar mass | 271.283 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Trifluoromethyldeschloroketamine (TFMDCK) is a designer drug from the arylcyclohexylamine family, which is presumed to have similar properties to ketamine, a dissociative anesthetic drug with hallucinogenic and sedative effects. It has been sold over the internet since around 2016, though genuine samples appear to be rare.[1] The o-trifluoromethyl analogue of hydroxynorketamine has also been researched as an antidepressant.[2]
See also
- Bromoketamine
- Deschloroketamine
- Methoxyketamine
- Methoxmetamine
References
- ↑ Wallach J, Brandt SD (2018). "1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances". Handbook of Experimental Pharmacology. 252: 305–352. doi:10.1007/164_2018_148. ISBN 978-3-030-10560-0. PMID 30196446.
- ↑ 种长效化合物的制备方法. Chinese patent CN 110540510A, 18 June 2019
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.